Vanguard Information Technology ETF (VGT)
| Assets | $62.21B |
| Expense Ratio | 0.10% |
| PE Ratio | 36.08 |
| Shares Out | 125.92M |
| Dividend (ttm) | $3.61 |
| Dividend Yield | 0.74% |
| Ex-Dividend Date | Mar 22, 2024 |
| Payout Ratio | 26.78% |
| 1-Year Return | +29.20% |
| Volume | 1,055,855 |
| Open | 484.19 |
| Previous Close | 479.90 |
| Day's Range | 479.32 - 488.63 |
| 52-Week Low | 368.39 |
| 52-Week High | 536.63 |
| Beta | 1.39 |
| Holdings | 316 |
| Inception Date | Jan 26, 2004 |
About VGT
Fund Home PageThe Vanguard Information Technology ETF (VGT) is an exchange-traded fund that mostly invests in information technology equity. The fund tracks a market cap-weighted index of companies in the US information technology sector. VGT was launched on Jan 26, 2004 and is issued by Vanguard.
Top 10 Holdings
60.10% of assets| Name | Symbol | Weight |
|---|---|---|
| Microsoft Corporation | MSFT | 18.32% |
| Apple Inc | AAPL | 15.38% |
| NVIDIA Corporation | NVDA | 11.76% |
| Broadcom Inc. | AVGO | 4.24% |
| Salesforce, Inc. | CRM | 2.11% |
| Advanced Micro Devices, Inc. | AMD | 2.11% |
| Adobe Inc. | ADBE | 1.65% |
| Accenture plc | ACN | 1.57% |
| Oracle Corporation | ORCL | 1.50% |
| Cisco Systems, Inc. | CSCO | 1.46% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 22, 2024 | $1.259 | Mar 27, 2024 |
| Dec 19, 2023 | $0.7946 | Dec 22, 2023 |
| Sep 28, 2023 | $0.8814 | Oct 3, 2023 |
| Jun 29, 2023 | $0.6757 | Jul 5, 2023 |
| Mar 24, 2023 | $0.7716 | Mar 29, 2023 |
| Dec 15, 2022 | $0.872 | Dec 20, 2022 |
News
Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The ...
Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic Surgeons
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that new results from the Phase 2 clinical program evaluati...
Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience Initiates Phase 2 VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries.
Nvidia's Stock Slide Has Taken a Toll on Semiconductor ETFs
Nvidia (NVDA) shares tumbled almost 9% last week after U.S. government officials announced more stringent curbs on exports of advanced AI chips to China, dragging down many technology-centric exchange...
Apple's Rough Week Dragged Many of the Biggest ETFs Down With It
Apple (AAPL) shares had a rough week, tumbling almost 6% and dragging down a number of popular exchange-traded funds (ETFs) that are heavily exposed to the world's most valuable company.
Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer.
ETFs Gain Popularity With Retail Investors
Active traders in the U.S. remain confident the funds can generate returns.
Investors Dump Stock ETFs Ahead Of CPI Data
The S&P 500 is down 16% from its highs, not far from the bear market threshold.
Investors Fade Post-Fed Rally As Rates Spike
The U.S. 10-year Treasury yield hit a new high today, spooking equity investors.
Stock ETFs Test Crucial Area Amid Mounting Worries
The S&P 500 is down 13% from its highs, matching its low point from March. Can it hold here?
Tech, High Growth ETFs Buckle Amid Spiking Rates
The 10-year Treasury bond yield rallied for its seventh-straight session, pressuring high growth and high valuation stocks.
GICS Reveals Sector Shifts For 2023
The joint S&P Dow Jones-MSCI sector system scaled back its changes for 2023.
ETFs React To First Fed Rate Hike Since 2018
The Fed boosted rates, but stock ETFs rallied.
First Look At Possible GICS Shakeup
Renewable energy stocks may move to energy sector; PayPal and MasterCard could leave tech space.
ETFs Tumble On Worst Start To Year Ever For Stocks
The tech rout has spread to the broader markets.
Top Tech ETFs For October
Tech has boomed during these treacherous times, with and without stimulus, and with and without COVID spikes. But how sustainable is this?
Best Tech ETFs For August As Sector Drives Growth In Markets
Tech ETFs have also been a blessing for investors as they continue to receive inflows over the period. Economic indicators present a mixed picture with no clear indication of how the economy will evol...